Skip to main content
. 2010 Jul 22;116(22):4436–4438. doi: 10.1182/blood-2010-05-287417

Figure 1.

Figure 1

Patient distribution and outcomes on E4903 on the use of lenalidomide plus a prednisone taper in subjects with myelofibrosis. IWG-MRT spleen response8: > 50% reduction in palpable component below the left costal margin (for spleen > 10 cm at baseline), complete absence of palpable component if < 10 cm at baseline. IWG-MRT anemia response8: > 2 g/dL improvement in hemoglobin or becoming transfusion independent (if originally transfusion dependent).